In a nutshell This trial is aiming to examine the safety and effectiveness of experimental treatment DF6002 alone or in combination with nivolumab (Opdivo) in the treatment of advanced solid tumors, including melanoma. The main outcomes to be measured are drug toxicity, and response rate of patients to the drug. This trial is being...
Read MoreIn a nutshell This study compared the effectiveness of current treatment options for high-risk prostate cancer (PCa). It found that RP is the preferred treatment option for these patients. Some background Prostate surgery (RP) is a common treatment option for high-risk PCa. Radiation therapy (RT), androgen deprivation therapy...
Read MoreIn a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...
Read MoreIn a nutshell This trial is examining the effectiveness of radiation therapy with or without apalutamide (Erleada) in the treatment of stage 3-4 prostate cancer. The main outcome to be measured will be survival without cancer worsening. This trial is recruiting in Canada and the United States. The details Radiation therapy uses high energy x-ray...
Read MoreIn a nutshell This study aimed to investigate the best timing of treatment verification imaging used in radiation therapy for patients with prostate cancer. This study found that patients undergoing daily imaging had less risk of their cancer returning and had reduced rectal side-effects. Some background One main treatment option for prostate cancer...
Read MoreIn a nutshell The aim of this trial is to determine the effectiveness of a combination of the chemotherapies docetaxel (Taxotere) and carboplatin (Paraplatin) in advanced (spread beyond the prostate) prostate cancer. The main outcome to be measured is the number of patients who experience a decrease of 50% in prostate specific...
Read MoreIn a nutshell The aim of this study was to examine the benefit of adding radiation therapy to androgen deprivation therapy (ADT) for metastatic prostate cancer. Researchers reported a significant survival advantage when radiation therapy was combined with ADT. Some background Metastatic prostate cancer is cancer that has spread from the prostate...
Read MoreIn a nutshell This study compared the side effects of external beam radiation therapy (EBRT) and hypofractioned EBRT (H-EBRT) on erectile and sexual function. Researchers reported similar effects of EBRT and H-EBRT on erectile and sexual function up to 3 years after treatment. Some background Radiation therapy is a common treatment for localized...
Read MoreIn a nutshell This review evaluated recent evidence on the management of high-risk prostate cancer. Primary treatment options for high-risk prostate cancer were generally associated with good effectiveness, but authors advised that risk assessment is in need of refinement and standardization. Some background About 15% of men with prostate cancer...
Read MoreIn a nutshell This study investigated the relationship between lactate dehydrogenase (LDH) levels and cancer-specific survival. Researchers concluded that LDH can be used as an early indicator of cancer outcomes. Some background Early cancer detection methods have significantly improved cancer survival rates. There is increasing evidence to...
Read MoreIn a nutshell This phase I/II trial aims to determine the safety of administering shorter courses of radiation over a shorter period of time to patients who have had their prostate removed. The main outcome to be investigated is dose safety and toxicity in patients and to determine quality of life benefits. The details Radiation therapy...
Read MoreIn a nutshell The authors aimed to determine the effect of common treatments on prostate cancer-specific mortality for patients with intermediate-risk prostate cancer. Some background Intermediate-risk prostate cancer is cancer that has grown through and/or out of the prostate. It can be further classified as favorable or...
Read More
